Ensifentrine

Therapeutic Segment Chronic obstructive pulmonary disease

CAS No. 1884461-72-6

Development Status Under development

Molecule Type Small Molecule

Enquire Now

Mechanism of Action

Ensifentrine is a novel PDE3 and 4 inhibitor, the first inhaled treatment for respiratory diseases in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) resulting in bronchodilator and non-steroidal anti-inflammatory effects.

Disclaimer: No information in this Catalog – including any reference to any product or service – constitutes an offer for sale or be constructed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, under Bolar Provision the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of patent scenario for their respective markets and will be responsible for all patent related liabilities.